Health status in patients with coexistent COPD and heart failure:a validation and comparison between the Clinical COPD Questionnaire and the Minnesota by Berkhof, Farida F. et al.
  
 University of Groningen
Health status in patients with coexistent COPD and heart failure
Berkhof, Farida F.; Metzemaekers, Leola; Uil, Steven M.; Kerstjens, Huib A. M.; van den
Berg, Jan W. K.
Published in:
International Journal of Chronic Obstructive Pulmonary Disease
DOI:
10.2147/COPD.S66028
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2014
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Berkhof, F. F., Metzemaekers, L., Uil, S. M., Kerstjens, H. A. M., & van den Berg, J. W. K. (2014). Health
status in patients with coexistent COPD and heart failure: a validation and comparison between the Clinical
COPD Questionnaire and the Minnesota. International Journal of Chronic Obstructive Pulmonary Disease,
9, 999-1008. https://doi.org/10.2147/COPD.S66028
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
© 2014 Berkhof et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
International Journal of COPD 2014:9 999–1008
International Journal of COPD Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
999
O r I g I n a l  r e s e a r C h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/COPD.S66028
health status in patients with coexistent  
COPD and heart failure: a validation  
and comparison between the Clinical  
COPD Questionnaire and the Minnesota  





Jan WK van den Berg1
1Department of Pulmonary Diseases, 
Isala hospital, Zwolle, 2Department 
of Pulmonary Diseases, University 
Medical Center groningen, University 
of groningen, groningen research 
Institute for asthma and COPD, 
groningen, the netherlands
Correspondence: Farida F Berkhof 
Department of Pulmonary Diseases,  
Isala hospital, Dr van heesweg 2,  
8025aB, Zwolle, the netherlands 
Tel +313 8424 2456 
email f.f.berkhof@isala.nl
Background: Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are both 
common diseases that coexist frequently. Patients with both diseases have worse stable state health 
status when compared with patients with one of these diseases. In many outpatient clinics, health 
status is monitored routinely in COPD patients using the Clinical COPD  Questionnaire (CCQ) 
and in HF patients with the Minnesota Living with Heart Failure  Questionnaire (MLHF-Q). 
This study validated and compared which questionnaire, ie, the CCQ or the MLHF-Q, is suited 
best for patients with coexistent COPD and HF.
Methods: Patients with both COPD and HF and aged $40 years were included. Construct 
validity, internal consistency, test–retest reliability, and agreement were determined. The Short-
Form 36 was used as the external criterion. All questionnaires were completed at baseline. The 
CCQ and MLHF-Q were repeated after 2 weeks, together with a global rating of change.
Results: Fifty-eight patients were included, of whom 50 completed the study. Construct 
validity was acceptable. Internal consistency was adequate for CCQ and MLHF-Q total and 
domain scores, with a Cronbach’s alpha $0.70. Reliability was adequate for MLHF-Q and CCQ 
total and domain scores, and intraclass correlation coefficients were 0.70–0.90, except for the 
CCQ symptom score (intraclass correlation coefficient 0.42). The standard error of measure-
ment on the group level was smaller than the minimal clinical important difference for both 
questionnaires. However, the standard error of measurement on the individual level was larger 
than the minimal clinical important difference. Agreement was acceptable on the group level 
and limited on the individual level.
Conclusion: CCQ and MLHF-Q were both valid and reliable questionnaires for assessment of 
health status in patients with coexistent COPD and HF on the group level, and hence for research. 
However, in clinical practice, on the individual level, the characteristics of both questionnaires 
were not as good. There is room for a questionnaire with good evaluative properties on the 
individual level, preferably tested in a setting of patients with COPD or HF, or both.
Keywords: Clinical COPD Questionnaire, Minnesota Living with Heart Failure Questionnaire, 
chronic obstructive pulmonary disease, heart failure
Introduction
Chronic obstructive pulmonary disease (COPD) is a major worldwide cause of mor-
bidity and mortality, and its prevalence is predicted to increase over the following 
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including an increased prevalence of cardiovascular disease 
in comparison with the general population.2 Nine percent 
to 41% of COPD patients have heart failure (HF).3 Both 
systemic conditions have certain pathophysiologic charac-
teristics in common, ie, the shared risk factor of smoking 
leading to low-grade systemic inflammation, which in turn 
accelerates progression of atherosclerosis in both diseases.4 
COPD and HF also have overlapping clinical manifestations, 
like dyspnea, fatigue, and exercise intolerance.5,6 Managing 
patients with combined COPD and HF is a challenge because 
it is difficult to determine whether signs and symptoms are 
caused by COPD, HF, or both. This can lead to delays in 
adequate treatment, to more severe exacerbations, and to 
more frequent hospital admissions.7 Patients hospitalized 
with an exacerbation of COPD and HF have more hospital 
days, more readmissions, and higher mortality compared 
with COPD patients without HF.8 COPD patients with com-
bined disease also have more frequent exacerbations, leading 
to worse health status.9  Further, patients with coexistent 
COPD and HF have a worse health status in the stable state 
than patients with COPD only.10 Improving health status 
is a treatment goal in the follow-up of COPD patients.11 
Thus, it is important to monitor health status routinely in the 
outpatient clinic. Unfortunately, many patients have more 
than one chronic condition. This makes it difficult to use a 
single disease-specific health status questionnaire. In addi-
tion, measuring health status using  several questionnaires 
may be troublesome for the patient. For COPD patients, the 
most frequently used questionnaire in the Netherlands is the 
Clinical COPD Questionnaire (CCQ).12 For HF patients, the 
Minnesota Living with Heart Failure Questionnaire (MLHF-
Q) is most frequently used.13 Both health status question-
naires, ie, the CCQ and the MLHF-Q, are disease-specific 
questionnaires. Therefore, patients with coexistent COPD 
and HF theoretically have to complete both questionnaires, 
which is time-consuming and not practical in the outpatient 
clinic. One questionnaire to assess health status for patients 
with both diseases, ie, COPD and HF, would be ideal. Unfor-
tunately, no health status questionnaire has been constructed 
for patients with coexistent COPD and HF. Therefore, the 
aim of this study was to compare which existing question-
naire, the CCQ or the MLHF-Q, is suited best for patients 
with coexistent COPD and HF.
Materials and methods
study design
This single-center, prospective, validation study was carried 
out at Isala Hospital, a large teaching hospital in Zwolle, 
the Netherlands. Stable patients with both HF and COPD were 
contacted by telephone and invited to participate in the study, 
and signed their informed consent. Approval was received 
from the local ethics committee (local number 11.10127).
Patients
Patients with COPD GOLD (Global Initiative for Chronic 
Obstructive Lung Disease) stage $2 (defined as a post-bron-
chodilator forced expiratory volume in one second [FEV
1
] 
,80% and a ratio of FEV
1
 to forced vital capacity of ,70%), 
HF (defined clinically as a syndrome in which patients have 
typical signs and symptoms of HF and a reduced left ven-
tricular ejection fraction or  diastolic  dysfunction14), New 
York Heart Association functional class $2, and aged 40–85 
years with a smoking history of $5 pack years, and able to 
provide written informed consent were included. Patients 
who were not able to complete questionnaires on their own 
were excluded.
Data collection
Demographic characteristics, comorbidity (Charlson 
 Comorbidity Index), post-bronchodilator spirometry, 
 pro-B-type natriuretic peptide, and New York Heart 
 Association classification for HF were recorded at baseline. 
Construct validity, internal consistency, and floor and 
ceiling effects were determined by administering the CCQ, 
MLHF-Q, and Short-Form 36 (SF-36) at baseline. To assess 
reliability and responsiveness, all questionnaires together 
with the Global Rating of Change (GRC) were adminis-
tered at week 2 and week 12. Questionnaires were sent to 




The CCQ12 is a ten-item COPD-specific questionnaire with 
total, symptom, functional status, and mental status domains. 
A higher score indicates a worse health status. The minimal 
clinical important difference (MCID) of the CCQ total score 
is 0.4.15 The CCQ was developed without factor analysis 
because a discrepancy was found between factor analysis 
and expert opinion. After deliberation, clinicians and experts 
in the field of COPD management decided to forego factor 
analysis and to compose the domains themselves.12
Minnesota living with heart Failure Questionnaire
The MLHF-Q is a HF-specific questionnaire consisting 
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health status in COPD patients with coexistent heart failure
 leading to a total score and two domain scores, ie, physical 
and emotional state. A higher score indicates worse health 
status.13 The MCID was estimated at 4.8.16 The MLHF-Q 
was developed with factor analysis.13
short-Form 36
The SF-36 is a generic health status questionnaire with eight 
domains, ie, physical functioning, role physical, bodily pain, 
general health, vitality, social function, role emotional, and 
mental health.17–19 All scores are transformed to a range from 
0 to 100, with higher scores indicating better health status.
global rating of Change
The GRC was used to assess self-perceived change in health 
status, “To what extent have your pulmonary and/or cardiac 
symptoms changed in the past weeks?”, on a 15-point scale 
(−7 a very great deal worse, 0 no change, +7 a very great 
deal better).20
statistical analysis
Data analyses were performed using Statistical Package for 
the Social Sciences version 20.0 software (IBM Corpora-
tion, New York, NY, USA). Baseline characteristics are 
 presented as the mean (standard deviation) unless otherwise 
stated. In this study, the clinimetrics statistics definitions of 
the  COSMIN (Consensus-based standards for the selection 
of health status measurement instruments) study were fol-
lowed.21,22 First, one of the authors assessed face  validity, the 
degree to which the items of the CCQ and MLHF-Q indeed 
look to be an adequate reflection of the construct to be mea-
sured, namely “health status in patients with both, COPD 
and HF”. To assess content validity,22 the relevance and 
comprehensiveness of items in the CCQ and MLHF-Q were 
viewed and the subsequent four questions were answered, ie, 
“Do all items of the questionnaires refer to relevant aspects 
of the construct?”, “Are all items relevant for the study 
population?”, “Are all items relevant for the purpose of the 
application of the instrument?”, and “Do all items together 
comprehensively reflect the construct to be measured?”. To 
determine construct validity,  Spearman rank correlation 
coefficients of the CCQ, MLHF-Q, and SF-36 were used, 
because most of the distributions were skewed. The SF-36 
was used as the external criterion to assess construct valid-
ity. We predefined the hypotheses concerning the construct 
validity between corresponding domains: correlations ,0.30 
were considered as poor, correlations between 0.30–0.50 as 
moderate, and $0.50 as strong.22,23  Corresponding domains 
were defined as: CCQ total and MLHF-Q total score with 
all SF-36 domains. We expected the CCQ functional and 
MLHF-Q physical domains to  correspond with the SF-36 
domains physical functioning, social functioning, physical, 
and vitality; CCQ mental and MLHF-Q emotional domain 
with SF-36 domain mental health, social functioning, and 
role emotional; and CCQ symptom domain with SF-36 
domain pain and vitality, and we found that these domains 
did correspond with each other.  Correlations of ,0.1 were 
expected for FEV
1
 with MLHF-Q and CCQ total and domain 
scores. Construct validity was labeled as acceptable when 
$75% of the predefined hypotheses of the correspond-
ing domains agreed.22 Internal consistency of the CCQ, 
MLHF-Q, and SF-36 was assessed using Cronbach’s alpha 
coefficients; these were deemed adequate between 0.7 and 
0.9.24  Reliability, test–retest reliability, and agreement were 
evaluated in stable patients after 2 weeks (defined here as 
GRC −1, 0, and 1). Test–retest reliability was assessed 
with intraclass correlation coefficients (ICCs) based on the 
two-way random effects model and the standard error of 
measurement (SEM), and test–retest reliability was assumed 
sufficient when ICC was $0.7.24 Agreement was assessed 
with a Bland–Altman plot for the CCQ and MLHF-Q total 
score. Agreement was defined as acceptable when the limits 
of agreement were smaller than the MCID.24–26
Responsiveness would be determined with the receiver 
operating characteristics (ROC) and the area under the curve 
(AUC), an adequate AUC was declared when at least 0.70 
was declared as adequate.22,24 Floor and ceiling effects were 
assessed. When less than 15% of the patients achieved the 
highest or lowest  possible score respectively, floor and ceiling 
effects were labeled absent and the test adequate.22,25
Results
From October 25, 2011 to September 6, 2013, 58 patients 
were recruited and 50 completed the study, as shown in 
Figure 1. Patient demographic and clinical characteristics 
are presented in Table 1. All patients had COPD and HF; 
other common comorbidities were myocardial infarction 
(31, 53.4%), diabetes mellitus (12, 20.7%), and peripheral 
vascular disease (17, 29.3%).
Validity
Face validity
The CCQ and the MLHF-Q are both disease-specific 
questionnaires, separately designed for COPD and HF, 
respectively. For use in patients with both morbidities, 
the items of both questionnaires have to reflect the con-
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43 patients refused to participate 




























4 patients lost to follow up
1 palliative sedation
1 patient lost to follow up
CCQ
MLHF-Q
Figure 1 Flow chart showing the recruitment and retention of the study participants.
Note: In total 58 patients were included in the study, and 50 patients completed the study.
Abbreviations: CCQ, Clinical COPD Questionnaire; MlhF-Q, Minnesota for living with heart Failure Questionnaire; sF-36, short-Form 36; grC, global rating of Change.
Health status in patients with COPD and HF will partly 
derive from the severity of symptoms, ie, dyspnea, edema, 
orthopnea, cough, and phlegm. When the questionnaires 
are compared, the question “Did your HF prevent you 
from living as you wanted during the past month by 
causing swelling in your ankles or legs?” is missing in 
the CCQ, and the questions “How much of the time did 
you cough?” and “How much of the time did you pro-
duce phlegm?” were missing in the MLHF-Q. Except 
for the question about “ankle edema”, all other questions 
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health status in COPD patients with coexistent heart failure
Table 1 Patient characteristics
n 58
sex, male, n (%) 43 (74.1)
age (years), mean (sD) 73 (6)
Pack years, median (range) 37.5 (5–102)
Current smoker, n (%) 17 (29.3)
Oxygen therapy, n (%) 11 (19)
BMI, mean (sD) 27 (5)







 3 16 (27.6)
 4 13 (22.4)





 3 14 (24.1)
 4 3 (5.2)




 3 24 (41.4)
 $4 22 (37.9)
CCQ total score, mean (sD) 2.7 (1.1)
MlhF-Q, mean (sD) 43 (22)
sF-36, general health, mean (sD) 31 (18)
Notes: an=57. COPD classification by post-bronchodilator spirometry according 
to gOlD guidelines.
Abbreviations: BMI, body mass index; FeV1, forced expiratory volume in one 
second; gOlD, global Initiative for Chronic Obstructive lung Disease; pro-
BnP, pro-B-type natriuretic peptide; nYha, new York heart association; CCQ, 
Clinical COPD Questionnaire; MlhF-Q, Minnesota for living with heart Failure 
Questionnaire; sF-36, short-Form 36; sD, standard deviation.
Content validity
1. “Do all items of the CCQ and MLHF-Q refer to rel-
evant aspects of health status in patients with COPD 
and HF?” Originally, the CCQ was developed and 
validated in COPD patients,12 and the MLHF-Q was 
developed and validated in patients with HF.13 Since 
symptoms in COPD patients and in HF patients show 
considerable overlap, most of the items in both ques-
tionnaires reflect health status for both diseases, ie, 
COPD and HF.
2. “Are all items relevant for patients with COPD and 
HF?” The CCQ lacks an item about ankle edema,12 and 
the MLHF-Q lacks items about cough and phlegm.13 All 
other items are similar for both questionnaires.
3. “Are all items relevant for the purpose of application 
of the CCQ and MLHF-Q?” Ideally, a disease-specific 
questionnaire for patients with both COPD and HF should 
be developed, and should have good discriminative and 
evaluative properties. However, both questionnaires12,13 
are largely equal, and theoretically the authors consider 
therefore that both questionnaires perhaps can be used in 
patients with COPD and HF.
4. “Do all items together comprehensively reflect health 
status in patients with COPD and HF?” Based on 
previous validation studies,12,27,28 the CCQ reflects 
health status in COPD patients but is also validated 
in other patient populations, including patients with 
 laryngotracheal stenosis. The MLHF-Q reflects health 
status in HF patients,13 patients with atrial fibrillation,29 
and patients with heart valve surgery.30  Comprehensive 
evaluation of health status in patients with both 
COPD and HF has not been assessed yet for either 
questionnaire.
Construct validity
The correlation coefficients between the corresponding 
domains of the CCQ and the MLHF-Q with the external 
criterion, the SF-36, are shown in Table 2. Most of the 
 corresponding domains between the SF-36 and the CCQ 
and MLHF-Q show moderate to strong correlations, except 
for the SF-36 role emotional domain and the corresponding 
MLHF-Q emotional domain (−0.27) and the SF-36 role 
physical and the corresponding MLHF-Q physical domain 
(−0.29). Convergent validity is depicted in Table 3. As 
hypothesized, all corresponding domains of the CCQ and 
the MLHF-Q had strong correlations ($0.50). Conversely, 
correlations between the CCQ and MLHF-Q questionnaires 
and FEV
1
 percent predicted were indeed low, although 
some did slightly surpass the 0.1 boundary (Table 3). The 
predefined hypothesis for the corresponding domains of the 
CCQ, MLHF-Q, SF-36, and FEV
1
 percent predicted agreed 
in 75% of cases.
reliability
Internal consistency
All Cronbach’s alpha values were .0.7, implying 
 satisfactory internal consistency for the CCQ and MLHF-Q 
total and domain scores and most of the SF-36 domain 
scores, except for the domains general health (0.63) and 
social (0.69, see Table 4).
Test–retest reliability
The ICC was tested in 33 patients who remained stable after 
2 weeks and was adequate ($0.7) for all questionnaires, 
ie, the CCQ, MLHF-Q, and SF-36, indicating good 
test–retest reliability (Table 5). The only exceptions that 
had lower ICCs were: the CCQ symptom score (0.42 
[0.11, 0.66]), SF-36 physical functioning (0.64 [0.32, 
0.82]), and SF-36 role emotional (0.24 [−0.13, 0.53]). 
The SEMs of the total and domain scores of all ques-
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Table 2 Construct validity (n=58)
CCQ
Total Functional Mental Symptom
sF-36
 general health −0.57 (,0.001) −0.53 (,0.001) −0.30 (0.02) −0.51 (,0.001)
 role physical −0.32 (0.01) −0.25 (0.06) −0.21 (0.11) −0.26 (0.05)
 Pain −0.44 (0.001) −0.36 (0.006) −0.36 (0.006) −0.31 (0.02)
 Physical functioning −0.63 (,0.001) −0.77 (,0.001) −0.44 (0.001) −0.34 (0.008)
 Vitality −0.65 (,0.001) −0.50 (,0.001) −0.60 (,0.001) −0.53 (,0.001)
 social functioning −0.62 (,0.001) −0.60 (,0.001) −0.59 (,0.001) −0.38 (0.003)
 role emotional −0.30 (0.02) −0.23 (0.09) −0.33 (0.01) −0.22 (0.10)




 general health −0.50 (,0.001) −0.48 (,0.001) −0.38 (0.004)
 role physical −0.37 (0.005) −0.29 (0.03) −0.34 (0.008)
 Pain −0.40 (0.002) −0.37 (0.004) −0.36 (0.006)
 Physical functioning −0.51 (,0.001) −0.63 (,0.001) −0.29 (0.03)
 Vitality −0.64 (,0.001) −0.61 (,0.001) −0.53 (,0.001)
 social functioning −0.61 (,0.001) −0.62 (,0.001) −0.60 (,0.001)
 role emotional −0.33 (0.01) −0.27 (0.04) −0.27 (0.05)
 Mental health −0.53 (,0.001) −0.46 (,0.001) −0.60 (,0.001)
Notes: Construct validity is presented with spearman rank correlations (P-value). Correlations of the corresponding domains of $0.5 are adequate according to the 
hypothesis described in the statistical section.
Abbreviations: CCQ, Clinical COPD Questionnaire; sF-36, short Form 36; MlhF-Q, Minnesota for living with heart Failure Questionnaire.
level, except for the MLHF-Q emotional domain 
(SEM 2.02).
agreement
Bland–Altman plots of the CCQ total score and MLHF-Q 
total score for the 33 patients who remained stable after 
2 weeks are shown in Figure 2. The mean difference after 
2 weeks was −0.26±0.14 for the CCQ total score and 
−3.64±2.15 for the MLHF-Q total score. The upper and 
lower limits of agreement were 1.35 and −1.87 for the CCQ 
total score. The MLHF-Q had an upper limit of agreement 
of 20.52 and a lower limit of agreement of −27.80.
Measurement of change
responsiveness
Patients in this study were in a stable phase of their disease, 
ie, HF and COPD. After inclusion, patients received no 
change in intervention and were not expected to improve 
much. Therefore, responsiveness could not be assessed in 
this study.
Interpretability
Floor effects (lowest score) were present in the CCQ men-
tal domain 36.2% and in the MLHF-Q emotional domain 
20.7%. The SF-36 showed floor effects for the domains role 
Table 3 Construct validity: convergent and divergent validity (n=58)
Convergent validitya MLHF-Q total MLHF-Q physical MLHF-Q emotional
CCQ total 0.84 (,0.001) 0.82 (,0.001) 0.57 (,0.001)
CCQ symptom 0.61 (,0.001) 0.54 (,0.001) 0.43 (,0.001)
CCQ functional 0.67 (,0.001) 0.72 (,0.001) 0.35 (0.007)
CCQ mental 0.69 (,0.001) 0.68 (,0.001) 0.65 (,0.001)
Divergent validityb CCQ total CCQ symptom CCQ functional CCQ mental
FeV1 % predicted −0.17 (0.20) −0.16 (0.23) −0.17 (0.20) 0.03 (0.85)
MLHF-Q total MLHF-Q physical MLHF-Q emotional
FeV1 % predicted 0.04 (0.76) 0.04 (0.74) 0.10 (0.46)
Notes: aadequate convergent validity is present if spearman rank correlations of the corresponding domains are $0.5 according to the hypothesis described in the statistical 
section; bspearman rank correlations of divergent validity were expected to be #0.1.
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health status in COPD patients with coexistent heart failure
The discriminative part of the psychometric properties, ie, 
validity, internal consistency, and test–retest reliability, were 
comparable for the CCQ and MLHF-Q. The only exception 
was the CCQ symptom score, in which weaker correlations 
were found for test–retest reliability and construct validity. The 
evaluative part, ie, agreement of the CCQ and MLHF-Q, was 
similarly limited in both. The psychometric properties of both 
questionnaires will be discussed separately. Because the CCQ 
and MLHF-Q have not been validated before in patients with 
both COPD and HF, we cannot compare our findings directly 
with similar validation studies. Therefore, to give some per-
spective and to quantify our findings, we compared our study 
with validation studies in other patient populations.
Construct validity was assessed between the external crite-
rion, ie, the SF-36, and both questionnaires, ie, the CCQ and 
MLHF-Q. Most of the correlations between the  corresponding 
domains of the SF-36 and the MLHF-Q were moderate to 
strong. Other validation studies29,30 in patients with atrial 
fibrillation and patients undergoing heart valve surgery 
found similar correlations between the SF-36 and MLHF-Q. 
Corresponding domains of the CCQ and SF-36 achieved 
moderate to strong correlations as well, and were comparable 
with most of the correlations found in the original validation 
study.12 The exception to this notion is the CCQ symptom 
domain, which seems to have lower correlations with SF-36 
in comparison with the original validation study in patients 
with COPD only.12 This might signify that the CCQ symptom 
domain is not a reflection of the most important symptoms of 
patients with combined COPD and HF. The symptoms in 
COPD and HF overlap partially; however, some symptoms 
are different, like orthopnea or edema.31 The CCQ symptom 
domain consists of four items: “Short of breath at rest?”, 
“Short of breath doing physical activities?”, “Did you 
cough?”, and “Did you produce phlegm?”. These questions 
reflect symptom-related health status for patients with COPD 
alone. Symptom-related health status for patients with both 
diseases, ie, COPD and HF, is probably more complex.
The test–retest reliability of the CCQ symptom domain 
was also limited, with an ICC of 0.42 (0.10, 0.66). Previous 
studies in other populations showed higher ICCs for the 
CCQ symptom domain; one study27 in patients with COPD 
in primary care found an ICC of 0.74 and another study28 in 
adults with laryngotracheal stenosis found an ICC of 0.94. 
We do not have an explanation for this, but have considered 
whether the low ICC in our study could be due to the fact that 
patients with both COPD and HF are a more  homogeneous 
population than expected. In that case, the variability of 












 general health 0.63
 Mental health 0.83
 role emotional 0.86
 role physical 0.91
 Physical functioning 0.88
 social functioning 0.69
 Vitality 0.80
 Pain 0.92
Notes: Internal consistency is assessed with the Cronbach’s α coefficient, a corr-
elation between 0.70 and 0.95 is considered as good internal consistency.
Abbreviations: CCQ, Clinical COPD Questionnaire; MlhF-Q, Minnesota for 
living with heart Failure Questionnaire; sF-36, short Form 36.
Table 5 Test–retest reliability (n=33)
ICC (95% CI) SEM
CCQ
 Total 0.70 (0.48, 0.84) 0.60
 Mental 0.75 (0.55, 0.87) 0.67
 symptom 0.42 (0.10, 0.66) 0.89
 Functional 0.79 (0.63, 0.89) 0.69
MlhF-Q
 Total 0.85 (0.71, 0.92) 8.96
 emotional 0.90 (0.80, 0.95) 2.02
 Physical 0.79 (0.62, 0.89) 5.17
sF-36
 general health 0.74 (0.54, 0.86) 9.35
 Mental health 0.79 (0.61, 0.89) 8.74
 role emotional 0.24 (−0.13, 0.65) 36.00
 role physical 0.90 (0.80, 0.95) 8.70
 Physical functioning 0.64 (0.32, 0.82) 25.75
 social functioning 0.80 (0.64, 0.90) 12.12
 Vitality 0.76 (0.57, 0.88) 11.54
 Pain 0.82 (0.67, 0.91) 12.19
Notes: Test–retest-reliability is presented with the ICC and 95% CI. ICC $0.70 
gives a positive rating for test–retest reliability. Only stable patients (global rating 
of Change −1, 0, 1).
Abbreviations: CCQ, Clinical COPD Questionnaire; MlhF-Q, Minnesota for 
living with heart Failure Questionnaire; sF-36, short-Form 36; seM, standard error 
of measurement; ICC, intraclass correlation coefficient; CI, confidence interval.
 emotional (25.9%) and physical functioning (75.9%) and 
ceiling effects (highest score) for the domains role emotional 
(50%) and pain (36.2%), as shown in Table 6.
Discussion
This is the first study comparing and validating the CCQ 
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scores on the CCQ symptom domain between patients is 
low and within patients are equally present, leading to a low 
ICC and hampering its use as a discriminative tool in patients 
with both COPD and HF.
The MLHF-Q physical domain consists of eight items, 
with six items containing questions about functional state 
and two items canvassing symptom-related health status, ie, 
“Did your heart failure prevent you from living as you wanted 
during the last month by making you short of breath?”, and 
“Did your heart failure prevent you from living as you wanted 
during the last month by making you tired, fatigued, or low on 
energy?”.13 The MLHF-Q physical domain has an adequate 
discriminative value in patients with COPD and HF, with 
an ICC of 0.79 (0.62, 0.89). Perhaps this is due to the com-
bination of functional state and symptoms-related  questions 
about health status in the MLHF-Q physical domain. 
The  discriminative value in patients with COPD and HF is 
adequate as well, with an ICC of 0.79 (0.63, 0.89).
The degree of interrelatedness between the items 
of the domains of the CCQ and the MLHF-Q, internal 
 consistency, were adequate, all Cronbach’s alpha coefficients 
were $0.70, and were comparable with previous validation 
studies12,13,30 in patients with COPD, heart valve surgery, 
or HF.
The SEM of the CCQ and MLHF-Q total and domain 
scores on the individual level was larger than the MCID of 
both questionnaires. This suggests that neither questionnaire 
could differentiate between a clinical relevant change and 
measurement error in our study. Two studies have addressed 
the SEM of the CCQ total score before and found SEMs of 
0.2932 and 0.21.33 However, these SEMs were determined in 
COPD patients without HF. In our study, an SEM of 0.60 was 
found for the CCQ total score. The standard measurement 
error can be calculated on group level and on individual level 
(per patient). The SEM on individual level can be interpreted 
and used in clinical practice in the outpatient clinic. The SEM 
on group level can be interpreted and used in groups, ie clini-
cal research. The SEMs on the group level for the CCQ total, 
symptom, functional, and mental scores were 0.10, 0.15, 0.12, 
and 0.11, respectively. The latter SEM values are all smaller than 
the MCID of the CCQ, 0.4 points. Thus, on the group level, the 
CCQ is able to differentiate a real change from measurement 
error. The SEMs for the MLHF-Q total, emotional, and physical 
score on the group level were 1.56, 0.35, and 0.90, respectively. 
Table 6 Floor and ceiling effect (n=58)
Mean (SD) Floor (%) Ceiling (%)
CCQ
 Total 2.7 (1.1) 1.7 0
 Mental 1.3 (1.4) 36.2 0
 symptom 3.0 (1.3) 1.7 1.7
 Functional 3.2 (1.4) 1.7 0
MlhF-Q
 Total 43.3 (22.5) 5.2 0
 emotional 7.2 (6.5) 20.7 0
 Physical 22.3 (10.9) 5.2 0
sF-36
 general health 31 (18.1) 3.4 0
 Mental health 72.4 (19.0) 0 5.2
 role emotional 60.3 (43.5) 25.9 50
 role physical 32.1 (25.2) 12.1 0
 Physical functioning 15.1 (31.0) 75.9 8.6
 social functioning 60.3 (27.4) 3.4 19
 Vitality 44.7 (31.0) 0 0
 Pain 66.2 (32.0) 1.7 36.2
Abbreviations: CCQ, Clinical COPD Questionnaire; MlhF-Q, Minnesota for 











































































Figure 2 agreement over time of CCQ total score and MlhF-Q total score in stable COPD patients. (A) agreement of the CCQ total score and (B) agreement of the 
MlhF-Q total score over 2 weeks in stable COPD patients (grC −1, 0, 1).
Notes: The bold flat line represents the mean difference over 2 weeks for the CCQ and MlhF-Q total scores. The dashed lines are the limits of agreement, 1.96× standard 
deviation. (n=33).
Abbreviations: COPD, chronic obstructive pulmonary disease; CCQ, Clinical COPD Questionnaire; MlhF-Q, Minnesota for living with heart Failure Questionnaire; 
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health status in COPD patients with coexistent heart failure
The MCID of the MLHF-Q is 4.8. Also, the MLHF-Q was able 
to differentiate clinically relevant change from measurement 
error in patients with COPD and HF on the group level.
Similar results were found for the agreement. Both ques-
tionnaires had large limits of agreement on the individual level, 
ie, 1.35 and −1.87 for the CCQ total score and 20.52 and −27.80 
for the MLHF-Q total score. On the group level, the limits of 
agreement were 0.23 and −0.32 for the CCQ total score and 3.5 
and −4.84 for the MLHF-Q. On the group level, the limits of 
agreement are smaller or comparable with the MCID for both 
questionnaires, indicating that a clinically relevant change in 
health status can be distinguished from measurement error.
This study has some limitations that are worth discuss-
ing. One limitation is that the responsiveness, ie, the abil-
ity of the CCQ and MLHF-Q to detect changes in health 
status over time, could not be assessed in this study because 
patients received no change in intervention. Therefore, no 
conclusion can be drawn regarding patients who improved 
or deteriorated versus those who remained stable. Most of 
the patients remained stable because no intervention was 
given. Another limitation is the use of the SF-36, a generic 
health status questionnaire, as the reference standard; ideally, 
a disease-specific health status questionnaire for patients 
with COPD and HF would be used. Unfortunately, there is 
no such questionnaire for these patients. We chose generic 
SF-36 because it is validated for both COPD and HF.34,35 The 
last limitation is the MCIDs used for the CCQ and MLHF-
Q. These MCIDs were determined for patients with either 
COPD or HF, but not in patients with combined disease. 
This could underestimate or overestimate interpretation of 
the agreement, because agreement was acceptable when the 
limits of agreement were smaller than the MCID.
In conclusion, both questionnaires, the CCQ and the 
MLHF-Q, are valid and reliable for patients with both COPD 
and HF on the group level, for instance in clinical research or 
validation studies. However, the CCQ symptom domain does 
not reflect all symptoms of patients with coexistent COPD 
and HF, limiting its usefulness in this setting. On the indi-
vidual level, ie, in clinical practice, the CCQ and MLHF-Q 
were not able to differentiate a real clinically relevant change 
from measurement error in patients with COPD and HF in 
this study. Ideally, a new questionnaire should be developed, 
whereby a more complete reflection of health status can be 
measured in patients with both COPD and HF.
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